Drug Profile

APD 418

Alternative Names: APD-418

Latest Information Update: 06 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arena Pharmaceuticals
Class Cardiovascular therapies; Heart failure therapies
Mechanism of Action Beta 3 adrenergic receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Acute heart failure

Most Recent Events

19 Sep 2022 Arena Pharmaceuticals terminates a phase-II trial in Acute heart failure in Poland, Germany, Greece, Serbia and USA (IV) due to business decision (EudraCT2020-006131-10; NCT05139615)
11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
04 Feb 2022 Arena pharmaceuticals has patent protection for APD 418 in USA, Japan, Australia, Europe and China (Arena pharmaceuticals form 10-k, February 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com